Sunshine Biopharma Inc. — Form S-1
Filed October 2, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 72/100
What the filing says
Sunshine Biopharma (SBFM, market cap ~$7.1M) filed an S-1 to register up to $7.0M in securities on a best-efforts basis via placement agent Aegis Capital Corp. The offering consists of up to 10.18M common units ($0.6876/unit, each with 1 common share + 2 Series D warrants), 10.18M pre-funded units (exercise price $0.00001), and 40.72M Series D warrants (exercise price $0.6876, 5-year term). Net proceeds estimated at ~$6.0M after 7% placement fees and 1% expense allowance. No minimum offering amount required; company intends net proceeds for general corporate purposes and working capital. Offering is expected to close by November 30, 2026.
Why this rating
Substantial capital raise (85% of current market cap) relative to company size; material dilution risk with potential 236% share increase post-offering. However, best-efforts structure and no minimum create execution uncertainty. Nasdaq compliance risks already disclosed (minimum bid price, market value requirements).
Price action (we called it neutral)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.